Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Theravance Biopharma, Inc. (NASDAQ: TBPH)
TBPH Stock Predictions and Ratings
WSX Rating:
BUY
WSX Forecast (1yr):
7.40%
Analyst Rating:
BUY
Analyst Forecast (1yr):
18.30%
TBPH Stock Analysis
TBPH
PE Ratio:
7.1
TBPH
PEG Ratio:
Not Available
TBPH
Forward EPS Growth (12 month):
0.00%
TBPH
PS Ratio:
7.5
TBPH
PSG Ratio:
Not Available
TBPH
Forward Revenue Growth (12 month):
0.00%
TBPH Articles
No data was found